SMS Pharmaceuticals Limited

SMS Pharmaceuticals Limited

SMS Pharmaceuticals Limited has informed the Exchange about change in Management. The Board of Directors have approved the re-appointment of Mr. Ramesh Babu Potluri as a Chairman and Managing Director of the Company for a term of 5 consecutive years. The company has also approved to give loan to SMS Peptides Private Limited, Subsidiary Company, up to an aggregate amount not exceeding Rs. 50 Crores.

SMS Pharmaceuticals Limited

SMS Pharmaceuticals Limited has announced its unaudited financial results for the first quarter ended June 30, 2026, with revenue from operations at Rs. 20,696.49 lakhs and profit before tax at Rs. 2,814.42 lakhs. The company has also approved the re-appointment of its Managing Director, Ramesh Babu Potluri, for a term of 5 years, and has decided to give a loan to its subsidiary, SMS Peptides Private Limited, up to Rs. 50 crores.

SMS Pharmaceuticals Limited

SMS Pharmaceuticals Limited has announced its financial results for the quarter ended June 30, 2026, with a standalone profit before tax of Rs. 2,814.42 lakhs. The company has also approved the re-appointment of its Managing Director, Mr. Ramesh Babu Potluri, for a term of 5 years. Additionally, the company has approved giving a loan to its subsidiary, SMS Peptides Private Limited, up to an aggregate amount of Rs. 50 crores.

SMS Pharmaceuticals Limited

SMS Pharmaceuticals Limited has informed the Exchange about the submission of copies of newspaper publication for information regarding the transfer of shares to Investor Education Protection Fund (IEPF) pertaining to the unpaid/unclaimed dividend for the financial year 2018-2019.

SMS Pharmaceuticals Limited

SMS Pharmaceuticals Limited has informed the Exchange about General Updates

SMS Pharmaceuticals Limited

SMS Pharmaceuticals Limited has informed the Exchange about General Updates regarding a police complaint lodged by the Company in the matter of claiming of shares through impersonation by certain persons. The police authorities have arrested one of the persons involved and the matter is currently under further investigation.

SMS Pharmaceuticals Limited

SMS Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 30th June, 2026.

SMS Pharmaceuticals Limited

SMS Pharmaceuticals Limited has responded to the National Stock Exchange's (NSE) query regarding a spurt in volume of its equity shares, stating that the company has been complying with all material event disclosures and has not withheld any price-sensitive information.

SMS Pharmaceuticals Limited

SMS Pharmaceuticals Limited has observed a significant increase in volume, prompting the exchange to write to the company for a response.

SMS Pharmaceuticals Limited

SMS Pharmaceuticals Limited has closed its trading window for insiders due to SEBI regulations, effective from July 1, 2026, until 48 hours after the declaration of Q1 FY2026-27 financial results.